EC Number | Application | Comment | Organism |
---|---|---|---|
3.4.21.59 | medicine | viruses utilizes the enzyme to trigger their infectivity and multiplication in lungs, an inhibitor may regulate the enzyme activity and viral infections in vivo | Sus scrofa |
EC Number | Crystallization (Comment) | Organism |
---|---|---|
3.4.21.59 | - |
Sus scrofa |
EC Number | General Stability | Organism |
---|---|---|
3.4.21.59 | heparin stabilizes the enzyme, retains about 50% activity in a low-salt solution after 2 h incubation at 25°C | Sus scrofa |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.4.21.59 | antipain | - |
Sus scrofa | |
3.4.21.59 | Aprotinin | - |
Sus scrofa | |
3.4.21.59 | benzamidine | - |
Sus scrofa | |
3.4.21.59 | diisopropylfluorophosphate | - |
Sus scrofa | |
3.4.21.59 | leupeptin | - |
Sus scrofa | |
3.4.21.59 | additional information | chymostatin, E64 and pestatin have no effect | Sus scrofa | |
3.4.21.59 | mucus protease inhibitor | - |
Sus scrofa |
EC Number | Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|---|
3.4.21.59 | mast cell | - |
Sus scrofa | - |
- |
EC Number | Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|---|
3.4.21.59 | 32000 | - |
4 * 32000, SDS-PAGE | Sus scrofa |
3.4.21.59 | 120000 | - |
gel filtration | Sus scrofa |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.21.59 | additional information | Sus scrofa | post-translational proteolytic cleavage of the precursors of the fusion glycoproteins of enveloped RNA viruses is indispensable for their fusion activity and infectivity, enzyme triggers infection by pneumotropic Sendai and influenza A viruses by processing | ? | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.4.21.59 | Sus scrofa | - |
pig | - |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|
EC Number | Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
---|---|---|---|---|
3.4.21.59 | 3930 | - |
- |
Sus scrofa |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.21.59 | Ac-Ser-Ile-Gln-Ser-Arg-4-methyl-coumarin 7-amide + H2O | synthetic substrate, relative activity 51.2% | Sus scrofa | ? | - |
? | |
3.4.21.59 | human influenza virus HA + H2O | - |
Sus scrofa | HA1 + HA2 | - |
? | |
3.4.21.59 | additional information | activity only toward substrates with Arg at the P1 position, only 0.3% and 0.1% activity with t-butyloxycarbonyl-Val-Leu-Lys-4-methylcoumarin 7-amide and Arg-4-methylcoumarin 7-amide, Suc-Ala-Pro-Ala-4-methylcoumarin 7-amide and Suc-Leu-Leu-Val-Leu-4-methylcoumarin 7-amide are no substrates | Sus scrofa | ? | - |
? | |
3.4.21.59 | additional information | post-translational proteolytic cleavage of the precursors of the fusion glycoproteins of enveloped RNA viruses is indispensable for their fusion activity and infectivity, enzyme triggers infection by pneumotropic Sendai and influenza A viruses by processing | Sus scrofa | ? | - |
? | |
3.4.21.59 | Pro-Phe-Arg-4-methyl-coumarin 7-amide + H2O | synthetic substrate, relative activity 3.9% | Sus scrofa | ? | - |
? | |
3.4.21.59 | t-butyloxycarbonyl-Gln-Ala-Arg-4-methyl-coumarin 7-amide + H2O | synthetic substrate, relative activity 100% | Sus scrofa | ? | - |
? | |
3.4.21.59 | t-butyloxycarbonyl-Gln-Arg-Arg-4-methyl-coumarin 7-amide + H2O | synthetic substrate, relative activity 26.0% | Sus scrofa | ? | - |
? | |
3.4.21.59 | t-butyloxycarbonyl-Gln-Gly-Arg-4-methyl-coumarin 7-amide + H2O | synthetic substrate, relative activity 63.3% | Sus scrofa | ? | - |
? | |
3.4.21.59 | t-butyloxycarbonyl-Glu(OBzl)-Ala-Arg-4-methyl-coumarin 7-amide + H2O | synthetic substrate, relative activity 67.3% | Sus scrofa | ? | - |
? | |
3.4.21.59 | t-butyloxycarbonyl-Glu(OBzl)-Gly-Arg-4-methyl-coumarin 7-amide + H2O | synthetic substrate, relative activity 26.3% | Sus scrofa | ? | - |
? | |
3.4.21.59 | t-butyloxycarbonyl-Glu-Lys-Lys-4-methyl-coumarin 7-amide + H2O | synthetic substrate, relative activity 1.6% | Sus scrofa | ? | - |
? | |
3.4.21.59 | t-butyloxycarbonyl-Gly-Lys-Arg-4-methyl-coumarin 7-amide + H2O | synthetic substrate, relative activity 10.9% | Sus scrofa | ? | - |
? | |
3.4.21.59 | t-butyloxycarbonyl-Ile-Glu-Gly-Arg-4-methyl-coumarin 7-amide + H2O | synthetic substrate, relative activity 3.5% | Sus scrofa | ? | - |
? | |
3.4.21.59 | t-butyloxycarbonyl-Leu-Arg-Arg-4-methyl-coumarin 7-amide + H2O | synthetic substrate, relative activity 5.9% | Sus scrofa | ? | - |
? | |
3.4.21.59 | t-butyloxycarbonyl-Leu-Gly-Arg-4-methyl-coumarin 7-amide + H2O | synthetic substrate, relative activity 30.0% | Sus scrofa | ? | - |
? | |
3.4.21.59 | t-butyloxycarbonyl-Leu-Lys-Arg-4-methyl-coumarin 7-amide + H2O | synthetic substrate, relative activity 14.4% | Sus scrofa | ? | - |
? | |
3.4.21.59 | t-butyloxycarbonyl-Phe-Ser-Arg-4-methyl-coumarin 7-amide + H2O | synthetic substrate, relative activity 36.3% | Sus scrofa | ? | - |
? | |
3.4.21.59 | t-butyloxycarbonyl-Val-Pro-Arg-4-methyl-coumarin 7-amide + H2O | synthetic substrate, relative activity 6.1% | Sus scrofa | ? | - |
? |
EC Number | Subunits | Comment | Organism |
---|---|---|---|
3.4.21.59 | tetramer | 4 * 32000, SDS-PAGE | Sus scrofa |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.4.21.59 | Mast cell tryptase | - |
Sus scrofa |
3.4.21.59 | tryptase | - |
Sus scrofa |
EC Number | pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|---|
3.4.21.59 | 7.5 | 8 | - |
Sus scrofa |
EC Number | pH Minimum | pH Maximum | Comment | Organism |
---|---|---|---|---|
3.4.21.59 | 6 | - |
no activity below | Sus scrofa |